Oncotelic Therapeutics, Inc. (OTLC)

0.0386 +0.0003 (+0.78%) As of 10:50AM EDT. Market open.

Oncotelic Therapeutics, Inc.

29397 Agoura Road
Suite 107
Agoura Hills, CA 91301
United States
650 635 7000
https://www.oncotelic.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 22

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Vuong Trieu Ph.D.	Chairman & CEO	N/A	N/A	1963
Mr. Amit Shah	Chief Financial Officer	N/A	N/A	1967
Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D.	Chief Medical Officer – Translation Medicine & Director	N/A	N/A	1952
Mr. Saranjit Saund	CBO & GM of AI Division	N/A	N/A	1958
Mr. Steven W. King	Consultant & Director	N/A	N/A	1964
Dr. Larn Hwang	Chief Scientific Officer	N/A	N/A	1963
Dr. Seymour Howard Fein M.D.	Chief Regulatory Officer & Chief Medical Officer	N/A	N/A	1949
Mr. Burcak Beser	CTO of AI Division	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it is developing CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies. The company is headquartered in Agoura Hills, California.

Corporate governance

Oncotelic Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.